MorphoSys AG (XSWX:MOR) Marketable Securities : CHF494.4 Mil (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. MorphoSys AG's Marketable Securities for the quarter that ended in Dec. 2023 was CHF494.4 Mil.

MorphoSys AG's annual Marketable Securities declined from Dec. 2021 (CHF905.8 Mil) to Dec. 2022 (CHF498.2 Mil) and declined from Dec. 2022 (CHF498.2 Mil) to Dec. 2023 (CHF494.4 Mil).

MorphoSys AG Marketable Securities Historical Data

The historical data trend for MorphoSys AG's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Marketable Securities Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

249.13

1,059.73

905.82

498.19

494.41

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Marketable Securities	Get a 7-Day Free Trial															498.19	495.18	475.51	-	494.41

MorphoSys AG Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

MorphoSys AG (XSWX:MOR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

MorphoSys AG Marketable Securities Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (XSWX:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany MOR:Austria

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.